SEATTLEMarch 4, 2021 / PRNewswire / – AGC Biologics, a leading global biopharmaceutical contract development and manufacturing (CDMO) organization, has announced the expansion of its Cell and Gene Therapy Center of Excellence in Milan, increasing capacity and capabilities in the field of Suspension of viral vectors are to be implemented.
With this expansion, AGC Biologics will add two floors to the center and install additional equipment on the current floor. The commissioning of the new systems is planned for 2022.
“I am delighted that we can offer our current and future cell and gene therapy customers even more of what they need from our location in Milan,” said the Chief Business Officer of AGC Biologics. Mark Womack. “This is just one of the important steps we are taking to keep up with the evolving demands of the market.”
“This investment is part of our global expansion plan for cell and gene therapy in Europe, Asia and the USA“explained Patricio massera, Chief Executive Officer of AGC Biologics. “All of our innovations and enhancements focus on the needs of our partners and the patients for whom they are made. I look forward to announcing further expansion plans soon. “
The expansion takes place less than a year after the successful takeover and integration of the former MolMed SpA facilities by AGC. The Milan site was the first GMP facility approved in Europe for ex vivo manufacturing of gene therapy products and has unique commercial manufacturing experience with two cell and gene therapy products. AGC Biologics is now one of the few CDMOs in the world to offer both plasmid production and end-to-end cell and gene therapy services.
About AGC Biologics:
AGC Biologics is a leading global biopharmaceutical contract development and manufacturing (CDMO) company with a strong commitment to the highest standard of service as we work side by side with our customers and partners every step of the way. We provide world-class development and manufacture of mammalian and microbial therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our worldwide network extends over the USA, Europe and Asia, with cGMP compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 1,600 people worldwide. Our commitment to continuous innovation fosters technical creativity to solve our customers’ most complex challenges, including specializing in fast-track projects and rare diseases. AGC Biologics is your trusted partner. More information is available at www.agcbio.com.
Logo – https://mma.prnewswire.com/media/624983/AGC_Biologics_logo_Logo.jpg
– .
